| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Uterine Cervical Neoplasms | 20 | 2023 | 367 | 2.310 |
Why?
|
| Puerto Rico | 39 | 2024 | 1413 | 2.010 |
Why?
|
| Papillomavirus Infections | 18 | 2022 | 376 | 1.760 |
Why?
|
| Neoplasms | 17 | 2023 | 1377 | 1.760 |
Why?
|
| Leukemia, Myeloid, Acute | 2 | 2022 | 38 | 0.930 |
Why?
|
| Papillomaviridae | 8 | 2015 | 142 | 0.850 |
Why?
|
| Terminal Care | 2 | 2021 | 54 | 0.830 |
Why?
|
| Papillomavirus Vaccines | 3 | 2022 | 174 | 0.800 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2022 | 11 | 0.770 |
Why?
|
| Early Detection of Cancer | 7 | 2023 | 449 | 0.770 |
Why?
|
| Registries | 5 | 2019 | 437 | 0.700 |
Why?
|
| Hospice Care | 1 | 2021 | 20 | 0.690 |
Why?
|
| Humans | 78 | 2024 | 43102 | 0.660 |
Why?
|
| Female | 64 | 2024 | 24698 | 0.650 |
Why?
|
| Vaginal Smears | 7 | 2013 | 63 | 0.620 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2021 | 133 | 0.610 |
Why?
|
| United States | 17 | 2024 | 5205 | 0.590 |
Why?
|
| Thyroid Neoplasms | 1 | 2019 | 50 | 0.580 |
Why?
|
| Breast Neoplasms | 9 | 2022 | 1723 | 0.580 |
Why?
|
| Aged | 31 | 2024 | 8214 | 0.570 |
Why?
|
| Adult | 43 | 2024 | 13872 | 0.530 |
Why?
|
| Lung Neoplasms | 2 | 2021 | 495 | 0.510 |
Why?
|
| Middle Aged | 41 | 2024 | 12222 | 0.480 |
Why?
|
| Patient Acceptance of Health Care | 7 | 2023 | 497 | 0.440 |
Why?
|
| Sunscreening Agents | 1 | 2014 | 11 | 0.440 |
Why?
|
| Sunlight | 1 | 2014 | 48 | 0.420 |
Why?
|
| Health Knowledge, Attitudes, Practice | 7 | 2022 | 989 | 0.420 |
Why?
|
| Adolescent | 19 | 2021 | 6081 | 0.420 |
Why?
|
| Risk Factors | 12 | 2022 | 3994 | 0.410 |
Why?
|
| Retrospective Studies | 12 | 2024 | 2544 | 0.410 |
Why?
|
| Young Adult | 17 | 2021 | 5080 | 0.410 |
Why?
|
| Multiple Myeloma | 2 | 2024 | 48 | 0.390 |
Why?
|
| Health Behavior | 3 | 2023 | 575 | 0.390 |
Why?
|
| Self Administration | 1 | 2013 | 69 | 0.380 |
Why?
|
| Specimen Handling | 1 | 2013 | 63 | 0.380 |
Why?
|
| Ambulatory Care | 1 | 2013 | 81 | 0.370 |
Why?
|
| Cyclonic Storms | 2 | 2024 | 80 | 0.370 |
Why?
|
| Incidence | 11 | 2024 | 1078 | 0.370 |
Why?
|
| SEER Program | 5 | 2024 | 164 | 0.370 |
Why?
|
| Environmental Exposure | 1 | 2014 | 256 | 0.360 |
Why?
|
| Genetic Testing | 1 | 2011 | 91 | 0.330 |
Why?
|
| Medicare | 3 | 2022 | 332 | 0.330 |
Why?
|
| Palliative Care | 2 | 2021 | 61 | 0.320 |
Why?
|
| Information Seeking Behavior | 1 | 2010 | 28 | 0.300 |
Why?
|
| Uterine Cervical Dysplasia | 5 | 2007 | 43 | 0.290 |
Why?
|
| Health Personnel | 2 | 2022 | 277 | 0.280 |
Why?
|
| DNA, Viral | 6 | 2015 | 311 | 0.280 |
Why?
|
| Attitude to Health | 2 | 2011 | 338 | 0.270 |
Why?
|
| Colorectal Neoplasms | 2 | 2023 | 512 | 0.260 |
Why?
|
| Endometrial Neoplasms | 4 | 2011 | 79 | 0.260 |
Why?
|
| Language | 2 | 2021 | 185 | 0.250 |
Why?
|
| Cancer Care Facilities | 2 | 2010 | 20 | 0.250 |
Why?
|
| Health Services Accessibility | 6 | 2021 | 706 | 0.250 |
Why?
|
| Communication Barriers | 1 | 2006 | 60 | 0.240 |
Why?
|
| Health Status Disparities | 3 | 2019 | 719 | 0.240 |
Why?
|
| Male | 20 | 2024 | 23409 | 0.230 |
Why?
|
| Decision Making | 2 | 2006 | 249 | 0.220 |
Why?
|
| Genital Neoplasms, Female | 1 | 2024 | 17 | 0.210 |
Why?
|
| Patient Education as Topic | 2 | 2019 | 235 | 0.210 |
Why?
|
| Mass Screening | 4 | 2012 | 541 | 0.210 |
Why?
|
| Aged, 80 and over | 10 | 2019 | 2853 | 0.210 |
Why?
|
| Benzodiazepines | 1 | 2023 | 21 | 0.200 |
Why?
|
| Caribbean Region | 5 | 2023 | 79 | 0.200 |
Why?
|
| Hospital Mortality | 1 | 2005 | 210 | 0.200 |
Why?
|
| Socioeconomic Factors | 4 | 2006 | 1234 | 0.200 |
Why?
|
| Monoclonal Gammopathy of Undetermined Significance | 1 | 2023 | 2 | 0.200 |
Why?
|
| Occult Blood | 1 | 2023 | 32 | 0.200 |
Why?
|
| Paraproteinemias | 1 | 2023 | 4 | 0.200 |
Why?
|
| Texas | 9 | 2010 | 457 | 0.200 |
Why?
|
| Cytogenetics | 1 | 2022 | 3 | 0.200 |
Why?
|
| Civil Defense | 1 | 2023 | 17 | 0.190 |
Why?
|
| Sexual Behavior | 4 | 2011 | 638 | 0.190 |
Why?
|
| Cervix Uteri | 2 | 2013 | 48 | 0.190 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2022 | 18 | 0.190 |
Why?
|
| Genetic Markers | 1 | 2022 | 150 | 0.190 |
Why?
|
| Prognosis | 3 | 2022 | 861 | 0.180 |
Why?
|
| Sex Factors | 4 | 2014 | 1028 | 0.180 |
Why?
|
| Quality of Life | 3 | 2021 | 616 | 0.170 |
Why?
|
| Practice Guidelines as Topic | 1 | 2022 | 223 | 0.170 |
Why?
|
| Agriculture | 3 | 2005 | 66 | 0.170 |
Why?
|
| Recombinant Proteins | 1 | 2022 | 518 | 0.170 |
Why?
|
| Population Surveillance | 2 | 2019 | 246 | 0.170 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2022 | 220 | 0.160 |
Why?
|
| Vaccination | 1 | 2022 | 355 | 0.160 |
Why?
|
| Healthcare Disparities | 2 | 2019 | 590 | 0.160 |
Why?
|
| Prevalence | 3 | 2018 | 1612 | 0.150 |
Why?
|
| Skin Neoplasms | 1 | 2021 | 178 | 0.150 |
Why?
|
| Evidence-Based Medicine | 1 | 2019 | 107 | 0.150 |
Why?
|
| Capacity Building | 1 | 2019 | 99 | 0.150 |
Why?
|
| Emergency Service, Hospital | 1 | 2021 | 278 | 0.150 |
Why?
|
| Uterine Neoplasms | 1 | 2019 | 53 | 0.140 |
Why?
|
| Social Class | 5 | 2011 | 291 | 0.140 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2018 | 53 | 0.140 |
Why?
|
| Mammography | 4 | 2009 | 212 | 0.130 |
Why?
|
| Survival Rate | 5 | 2021 | 355 | 0.130 |
Why?
|
| Health Services Misuse | 1 | 2017 | 20 | 0.130 |
Why?
|
| Case-Control Studies | 9 | 2006 | 1285 | 0.130 |
Why?
|
| Oncogene Proteins, Viral | 3 | 2005 | 25 | 0.130 |
Why?
|
| Logistic Models | 7 | 2015 | 1009 | 0.130 |
Why?
|
| Age Factors | 4 | 2014 | 1154 | 0.130 |
Why?
|
| Insulin Resistance | 2 | 2011 | 201 | 0.130 |
Why?
|
| Uterine Cervical Diseases | 2 | 2013 | 14 | 0.120 |
Why?
|
| Colonic Neoplasms | 1 | 2018 | 223 | 0.120 |
Why?
|
| Poverty | 2 | 2009 | 400 | 0.120 |
Why?
|
| Public Health | 1 | 2019 | 424 | 0.110 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2005 | 154 | 0.110 |
Why?
|
| Mexican Americans | 2 | 2009 | 226 | 0.110 |
Why?
|
| Protective Clothing | 1 | 2014 | 6 | 0.110 |
Why?
|
| Repressor Proteins | 3 | 2005 | 273 | 0.110 |
Why?
|
| Biomedical Research | 1 | 2019 | 502 | 0.110 |
Why?
|
| Unsafe Sex | 2 | 2012 | 162 | 0.110 |
Why?
|
| Multivariate Analysis | 4 | 2015 | 638 | 0.100 |
Why?
|
| Ovarian Neoplasms | 3 | 2002 | 415 | 0.100 |
Why?
|
| Anus Diseases | 1 | 2013 | 17 | 0.100 |
Why?
|
| Anal Canal | 1 | 2012 | 32 | 0.090 |
Why?
|
| Health Surveys | 1 | 2014 | 405 | 0.090 |
Why?
|
| Cultural Characteristics | 3 | 2011 | 128 | 0.090 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2014 | 226 | 0.090 |
Why?
|
| Latin America | 2 | 2023 | 55 | 0.090 |
Why?
|
| Biotechnology | 1 | 2011 | 15 | 0.090 |
Why?
|
| Survival Analysis | 3 | 2014 | 368 | 0.090 |
Why?
|
| Consumer Health Information | 1 | 2011 | 24 | 0.090 |
Why?
|
| Insurance, Health | 3 | 2022 | 145 | 0.090 |
Why?
|
| Marketing | 1 | 2011 | 45 | 0.090 |
Why?
|
| User-Computer Interface | 1 | 2011 | 74 | 0.090 |
Why?
|
| Self Care | 1 | 2012 | 175 | 0.090 |
Why?
|
| Health Promotion | 2 | 2009 | 704 | 0.090 |
Why?
|
| Comprehensive Health Care | 1 | 2010 | 11 | 0.080 |
Why?
|
| Neoplasm Staging | 5 | 2018 | 374 | 0.080 |
Why?
|
| Oropharyngeal Neoplasms | 1 | 2010 | 11 | 0.080 |
Why?
|
| Genotype | 1 | 2013 | 800 | 0.080 |
Why?
|
| Self Efficacy | 2 | 2009 | 215 | 0.080 |
Why?
|
| Evidence-Based Practice | 1 | 2010 | 50 | 0.080 |
Why?
|
| Human papillomavirus 16 | 2 | 2007 | 37 | 0.070 |
Why?
|
| Analgesics, Opioid | 2 | 2023 | 252 | 0.070 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2010 | 186 | 0.070 |
Why?
|
| Genital Neoplasms, Male | 1 | 2008 | 2 | 0.070 |
Why?
|
| Genital Diseases, Male | 1 | 2008 | 2 | 0.070 |
Why?
|
| Proportional Hazards Models | 3 | 2024 | 518 | 0.070 |
Why?
|
| Condylomata Acuminata | 1 | 2008 | 6 | 0.070 |
Why?
|
| Women's Health | 2 | 2006 | 160 | 0.070 |
Why?
|
| Educational Status | 1 | 2010 | 339 | 0.070 |
Why?
|
| Internet | 1 | 2010 | 236 | 0.070 |
Why?
|
| Trust | 1 | 2010 | 167 | 0.070 |
Why?
|
| Health Education | 1 | 2011 | 363 | 0.070 |
Why?
|
| Program Development | 1 | 2009 | 240 | 0.070 |
Why?
|
| Ploidies | 1 | 2007 | 7 | 0.070 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 2 | 2004 | 27 | 0.070 |
Why?
|
| RNA, Messenger | 3 | 2007 | 1271 | 0.070 |
Why?
|
| Chromosome Aberrations | 1 | 2007 | 61 | 0.060 |
Why?
|
| Cohort Studies | 3 | 2024 | 1759 | 0.060 |
Why?
|
| Qualitative Research | 1 | 2010 | 574 | 0.060 |
Why?
|
| Carcinoma | 1 | 2007 | 108 | 0.060 |
Why?
|
| Chromatin | 1 | 2007 | 186 | 0.060 |
Why?
|
| Cross-Sectional Studies | 5 | 2015 | 3156 | 0.060 |
Why?
|
| Adiponectin | 1 | 2006 | 59 | 0.060 |
Why?
|
| Air Pollutants, Occupational | 1 | 2005 | 10 | 0.060 |
Why?
|
| Patient Satisfaction | 1 | 2006 | 165 | 0.060 |
Why?
|
| Wood | 1 | 2005 | 16 | 0.060 |
Why?
|
| Survivors | 1 | 2006 | 152 | 0.060 |
Why?
|
| Patient Participation | 1 | 2006 | 94 | 0.060 |
Why?
|
| Physician-Patient Relations | 1 | 2006 | 148 | 0.060 |
Why?
|
| Transients and Migrants | 1 | 2005 | 42 | 0.060 |
Why?
|
| DNA-Binding Proteins | 2 | 2005 | 561 | 0.060 |
Why?
|
| Women | 1 | 2005 | 28 | 0.060 |
Why?
|
| Dust | 1 | 2005 | 57 | 0.050 |
Why?
|
| Insulin-Like Growth Factor II | 1 | 2004 | 25 | 0.050 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2004 | 7 | 0.050 |
Why?
|
| Vulvar Neoplasms | 1 | 2004 | 10 | 0.050 |
Why?
|
| Odds Ratio | 4 | 2010 | 587 | 0.050 |
Why?
|
| Quality of Health Care | 1 | 2005 | 161 | 0.050 |
Why?
|
| Acculturation | 1 | 2005 | 205 | 0.050 |
Why?
|
| Lymph Nodes | 1 | 2004 | 74 | 0.050 |
Why?
|
| Analysis of Variance | 1 | 2005 | 575 | 0.050 |
Why?
|
| Risk Assessment | 4 | 2010 | 863 | 0.050 |
Why?
|
| Peptide Fragments | 1 | 2005 | 307 | 0.050 |
Why?
|
| Pilot Projects | 3 | 2012 | 760 | 0.050 |
Why?
|
| Antibodies, Viral | 1 | 2005 | 306 | 0.050 |
Why?
|
| Guam | 1 | 2023 | 83 | 0.050 |
Why?
|
| Efficiency | 1 | 2003 | 14 | 0.050 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2003 | 81 | 0.050 |
Why?
|
| Cystadenocarcinoma, Papillary | 1 | 2002 | 3 | 0.050 |
Why?
|
| Research Design | 1 | 2005 | 385 | 0.050 |
Why?
|
| Peritoneal Neoplasms | 1 | 2002 | 18 | 0.050 |
Why?
|
| Precancerous Conditions | 1 | 2003 | 83 | 0.050 |
Why?
|
| Gynecology | 1 | 2003 | 35 | 0.050 |
Why?
|
| Menopause | 1 | 2003 | 64 | 0.050 |
Why?
|
| Behavioral Risk Factor Surveillance System | 1 | 2023 | 82 | 0.050 |
Why?
|
| Education, Medical, Graduate | 1 | 2003 | 61 | 0.050 |
Why?
|
| Cystadenocarcinoma, Serous | 1 | 2002 | 44 | 0.050 |
Why?
|
| Adenofibroma | 1 | 2002 | 1 | 0.050 |
Why?
|
| Disease-Free Survival | 2 | 2018 | 116 | 0.050 |
Why?
|
| Thyroid Diseases | 1 | 2002 | 6 | 0.050 |
Why?
|
| Confidence Intervals | 3 | 2010 | 162 | 0.050 |
Why?
|
| Mentors | 1 | 2003 | 145 | 0.040 |
Why?
|
| Endometriosis | 1 | 2002 | 83 | 0.040 |
Why?
|
| Disease Progression | 1 | 2023 | 667 | 0.040 |
Why?
|
| Emotions | 1 | 2023 | 254 | 0.040 |
Why?
|
| Data Collection | 2 | 2015 | 210 | 0.040 |
Why?
|
| Pamphlets | 1 | 2019 | 27 | 0.040 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 3 | 2006 | 458 | 0.040 |
Why?
|
| Chronic Disease | 1 | 2023 | 549 | 0.040 |
Why?
|
| Medical Tourism | 1 | 2019 | 4 | 0.040 |
Why?
|
| International Cooperation | 1 | 2019 | 52 | 0.040 |
Why?
|
| International Agencies | 1 | 2019 | 6 | 0.040 |
Why?
|
| Sex Distribution | 2 | 2010 | 224 | 0.040 |
Why?
|
| Medical Oncology | 1 | 2019 | 50 | 0.040 |
Why?
|
| Developing Countries | 1 | 2019 | 113 | 0.040 |
Why?
|
| Cause of Death | 1 | 2019 | 186 | 0.040 |
Why?
|
| Tumor Virus Infections | 2 | 2010 | 22 | 0.030 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2017 | 24 | 0.030 |
Why?
|
| Mastectomy, Segmental | 1 | 2017 | 25 | 0.030 |
Why?
|
| Age Distribution | 2 | 2010 | 249 | 0.030 |
Why?
|
| Hospitalization | 1 | 2021 | 485 | 0.030 |
Why?
|
| Diet | 1 | 2003 | 826 | 0.030 |
Why?
|
| Delivery of Health Care | 1 | 2019 | 310 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2017 | 341 | 0.030 |
Why?
|
| Interviews as Topic | 2 | 2009 | 452 | 0.030 |
Why?
|
| Papillomavirus E7 Proteins | 2 | 2005 | 17 | 0.030 |
Why?
|
| California | 2 | 2009 | 548 | 0.030 |
Why?
|
| Pregnancy | 2 | 2011 | 1772 | 0.030 |
Why?
|
| Predictive Value of Tests | 2 | 2007 | 440 | 0.030 |
Why?
|
| Insurance Coverage | 2 | 2005 | 110 | 0.030 |
Why?
|
| Body Mass Index | 2 | 2011 | 925 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2015 | 259 | 0.030 |
Why?
|
| Sentinel Surveillance | 1 | 2014 | 25 | 0.030 |
Why?
|
| Nutrition Surveys | 1 | 2015 | 263 | 0.030 |
Why?
|
| Aging | 1 | 2019 | 783 | 0.030 |
Why?
|
| Cost of Illness | 1 | 2014 | 98 | 0.030 |
Why?
|
| Mexico | 2 | 2005 | 298 | 0.020 |
Why?
|
| Ambulatory Care Facilities | 1 | 2012 | 68 | 0.020 |
Why?
|
| Risk-Taking | 1 | 2015 | 457 | 0.020 |
Why?
|
| Child | 2 | 2011 | 3443 | 0.020 |
Why?
|
| Coitus | 1 | 2011 | 12 | 0.020 |
Why?
|
| Comorbidity | 1 | 2014 | 737 | 0.020 |
Why?
|
| Multimedia | 1 | 2011 | 18 | 0.020 |
Why?
|
| Pregnancy in Adolescence | 1 | 2011 | 34 | 0.020 |
Why?
|
| Parity | 1 | 2011 | 59 | 0.020 |
Why?
|
| Oklahoma | 1 | 2010 | 28 | 0.020 |
Why?
|
| Public-Private Sector Partnerships | 1 | 2010 | 17 | 0.020 |
Why?
|
| Alaska | 1 | 2010 | 62 | 0.020 |
Why?
|
| Community Health Planning | 1 | 2010 | 38 | 0.020 |
Why?
|
| Micronesia | 1 | 2010 | 90 | 0.020 |
Why?
|
| Medical History Taking | 1 | 2010 | 38 | 0.020 |
Why?
|
| Population Groups | 1 | 2010 | 59 | 0.020 |
Why?
|
| Reference Values | 1 | 2010 | 211 | 0.020 |
Why?
|
| Program Evaluation | 1 | 2011 | 359 | 0.020 |
Why?
|
| Head and Neck Neoplasms | 1 | 2010 | 81 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2011 | 490 | 0.020 |
Why?
|
| Sexually Transmitted Diseases | 1 | 2011 | 174 | 0.020 |
Why?
|
| Schools | 1 | 2011 | 283 | 0.020 |
Why?
|
| Curriculum | 1 | 2011 | 318 | 0.020 |
Why?
|
| Respiratory Tract Infections | 1 | 2008 | 36 | 0.020 |
Why?
|
| Sexual Partners | 1 | 2011 | 326 | 0.020 |
Why?
|
| Anus Neoplasms | 1 | 2008 | 44 | 0.020 |
Why?
|
| Image Cytometry | 1 | 2007 | 6 | 0.020 |
Why?
|
| Human papillomavirus 18 | 1 | 2007 | 6 | 0.020 |
Why?
|
| Indians, North American | 1 | 2010 | 192 | 0.020 |
Why?
|
| Models, Statistical | 1 | 2009 | 195 | 0.020 |
Why?
|
| Virus Integration | 1 | 2007 | 65 | 0.020 |
Why?
|
| Biopsy | 1 | 2007 | 177 | 0.020 |
Why?
|
| Psychometrics | 1 | 2009 | 358 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2011 | 1600 | 0.020 |
Why?
|
| Hela Cells | 1 | 2007 | 376 | 0.020 |
Why?
|
| Outpatients | 1 | 2006 | 37 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2007 | 455 | 0.020 |
Why?
|
| Medically Uninsured | 1 | 2006 | 65 | 0.010 |
Why?
|
| Time Factors | 1 | 2010 | 1857 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2007 | 652 | 0.010 |
Why?
|
| RNA, Viral | 1 | 2007 | 321 | 0.010 |
Why?
|
| New Mexico | 1 | 2005 | 37 | 0.010 |
Why?
|
| Mucous Membrane | 1 | 2005 | 34 | 0.010 |
Why?
|
| Health Care Costs | 1 | 2006 | 91 | 0.010 |
Why?
|
| Immunoglobulin A | 1 | 2005 | 65 | 0.010 |
Why?
|
| Endometrium | 1 | 2006 | 59 | 0.010 |
Why?
|
| Infant | 1 | 2009 | 1175 | 0.010 |
Why?
|
| Matched-Pair Analysis | 1 | 2005 | 10 | 0.010 |
Why?
|
| Immunity, Cellular | 1 | 2005 | 74 | 0.010 |
Why?
|
| Guidelines as Topic | 1 | 2005 | 56 | 0.010 |
Why?
|
| Breast Self-Examination | 1 | 2005 | 13 | 0.010 |
Why?
|
| Diabetes Mellitus | 1 | 2011 | 539 | 0.010 |
Why?
|
| Likelihood Functions | 1 | 2005 | 62 | 0.010 |
Why?
|
| Physical Examination | 1 | 2005 | 45 | 0.010 |
Why?
|
| Health Care Surveys | 1 | 2005 | 152 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2009 | 1546 | 0.010 |
Why?
|
| Patient Compliance | 1 | 2006 | 233 | 0.010 |
Why?
|
| Immunoglobulin G | 1 | 2005 | 259 | 0.010 |
Why?
|
| Rosaniline Dyes | 1 | 2004 | 5 | 0.010 |
Why?
|
| Polymorphism, Genetic | 1 | 2005 | 201 | 0.010 |
Why?
|
| Lymph Node Excision | 1 | 2004 | 25 | 0.010 |
Why?
|
| Contraceptives, Oral | 1 | 2003 | 17 | 0.010 |
Why?
|
| Dietary Fats, Unsaturated | 1 | 2003 | 9 | 0.010 |
Why?
|
| Base Sequence | 1 | 2005 | 983 | 0.010 |
Why?
|
| Social Support | 1 | 2006 | 445 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2005 | 1180 | 0.010 |
Why?
|
| Fellowships and Scholarships | 1 | 2003 | 32 | 0.010 |
Why?
|
| Risk | 1 | 2003 | 287 | 0.010 |
Why?
|
| Dietary Fiber | 1 | 2003 | 51 | 0.010 |
Why?
|
| Adenocarcinoma, Clear Cell | 1 | 2002 | 21 | 0.010 |
Why?
|
| Carcinoma, Endometrioid | 1 | 2002 | 20 | 0.010 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2002 | 14 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2005 | 1542 | 0.010 |
Why?
|
| Diet Surveys | 1 | 2003 | 99 | 0.010 |
Why?
|
| Vitamin E | 1 | 2003 | 62 | 0.010 |
Why?
|
| Carotenoids | 1 | 2003 | 74 | 0.010 |
Why?
|
| Obesity | 1 | 2011 | 1151 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2004 | 611 | 0.010 |
Why?
|
| Mice, Nude | 1 | 2003 | 408 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2002 | 173 | 0.010 |
Why?
|
| Rural Population | 1 | 2005 | 373 | 0.010 |
Why?
|
| Mice, Transgenic | 1 | 2003 | 665 | 0.010 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2003 | 220 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2002 | 1067 | 0.010 |
Why?
|
| Hypertension | 1 | 2006 | 835 | 0.010 |
Why?
|
| Feeding Behavior | 1 | 2003 | 469 | 0.010 |
Why?
|
| Smoking | 1 | 2005 | 1024 | 0.010 |
Why?
|
| HIV Infections | 1 | 2011 | 2586 | 0.010 |
Why?
|
| Mice | 1 | 2003 | 6644 | 0.010 |
Why?
|
| Animals | 1 | 2003 | 16992 | 0.000 |
Why?
|